Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday

Nvidia said it entered a non‑exclusive licensing agreement with AI chip startup Groq, with NVDA trading around $190.16 in overnight Robinhood activity after a $188.61 close (down 0.3% on Wednesday). Sanofi’s announced acquisition of Dynavax sent DVAX up 38.2% to $15.38, while Sobr Safe revealed a private placement of 1.29 million shares at $1.55 plus warrants, lifting its stock 82.3% to $2.37. Davis Commodities reported H1 revenue of $95.0 million, a 42.1% y/y increase from $66.9 million, yet shares fell 8.9% to $0.24, and Biohaven disclosed a failed Phase 2 proof‑of‑concept for BHV‑7000 in MDD (shares +3% to $10.81).

Analysis

Market structure: Nvidia (NVDA) is the clear beneficiary — a non‑exclusive licensing deal accelerates platform adoption and pushes inference workloads toward established GPU ecosystems, strengthening Nvidia’s pricing power vs. specialist ASIC startups. Winners also include semicap and datacenter plays (ASML, LRCX, AMZN/GOOGL cloud) from increased chip build and colo demand; losers are small inference-only vendors and penny‑caps that rely on retail momentum.

Risk assessment: Key tail risks are antitrust/export‑control scrutiny of Nvidia (6–24 months), failed M&A approvals for Dynavax (DVAX) over 30–180 days, and dilution/pump‑and‑dump dynamics at SOBR after the $1.55 placement. Immediate volatility (days–weeks) will cluster around NVDA earnings and deal filings; medium term (3–12 months) depends on foundry/HBM supply and datacenter power constraints.

Trade implications: Tactical: position size and timing matter — favor measured exposure to NVDA (buy dips under $180; target $220 in 3–6 months) and pro‑semicap holdings (ASML, LRCX). Short or hedge microcaps (SOBR, DTCK) that just printed dilutive raises; avoid chasing DVAX beyond announced deal price and treat BHVN as a pipeline risk — reduce net long biotech exposure until further readouts.

Contrarian angles: The market may underprice regulatory friction from Nvidia’s ecosystem dominance and overprice small‑cap financing rallies (SOBR). Historical pattern: post‑placement penny stocks retrace 30–70% within 30–90 days; non‑exclusive licensing can both entrench Nvidia and invite scrutiny, so scale into positions and prefer option‑defined risk structures.

Key Decisions for Investors

• Establish a 1–2% long position in NVDA on pullbacks below $180, with a 3–6 month target of $220 and an 8% stop‑loss; hedge with a 3‑month 200/240 call spread to cap cost and retain upside.
• Add 0.5–1% exposure to ASML (ASML) or Lam Research (LRCX) as indirect beneficiaries of increased AI capex; scale in over 4–8 weeks if NVDA datacenter orders confirm strength.
• Initiate a 1–2% short or buy 60‑day puts on SOBR (SOBR) if shares remain >$2.25 after placement closes; target profit if price declines 30–50% or unwind at $1.00.
• Do NOT chase DVAX (DVAX) above the announced-acquisition price; if a firm buyout price is disclosed, consider arbitrage only after confirming deal terms and regulatory timeline (expect 30–180 day closing window).
• Reduce single‑name biotech exposure to BHVN by ~25% or buy 3–6 month puts if net exposure >2% of portfolio, pending clearer pipeline catalysts and next readouts.